Prevention of Bone Loss in a Model of Postmenopausal Osteoporosis through Adrenomedullin Inhibition by Martínez-Herrero, Sonia et al.
ORIGINAL RESEARCH
published: 30 June 2016
doi: 10.3389/fphys.2016.00280
Frontiers in Physiology | www.frontiersin.org 1 June 2016 | Volume 7 | Article 280
Edited by:
Geoffrey A. Head,
Baker IDI Heart and Diabetes Institute,
Australia
Reviewed by:
John M. Chirgwin,
Indiana University, USA
Takayuki Shindo,
Shinto University Graduate School of
Medicine, Japan
*Correspondence:
Alfredo Martínez
amartinezr@riojasalud.es
†
These authors have contributed
equally to this work and should be
considered co-first authors.
Specialty section:
This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology
Received: 17 February 2016
Accepted: 21 June 2016
Published: 30 June 2016
Citation:
Martínez-Herrero S, Larrayoz IM,
Ochoa-Callejero L, Fernández LJ,
Allueva A, Ochoa I and Martínez A
(2016) Prevention of Bone Loss in a
Model of Postmenopausal
Osteoporosis through Adrenomedullin
Inhibition. Front. Physiol. 7:280.
doi: 10.3389/fphys.2016.00280
Prevention of Bone Loss in a Model
of Postmenopausal Osteoporosis
through Adrenomedullin Inhibition
Sonia Martínez-Herrero 1†, Ignacio M. Larrayoz 1†, Laura Ochoa-Callejero 1,
Luis J. Fernández 2, 3, Alexis Allueva 2, 3, Ignacio Ochoa 2, 3 and Alfredo Martínez 1*
1 Angiogenesis Interest Group, Oncology Area, Center for Biomedical Research of La Rioja, Fundación Rioja Salud, Logroño,
Spain, 2Centro de Investigación Biomédica en Red, Aragon Institute of Health Sciences, Zaragoza, Spain, 3Group of
Structural Mechanics and Materials Modelling, Aragón Institute of Engineering Research (I3A), University of Zaragoza,
Zaragoza, Spain
Despite recent advances in the understanding and treatment options for osteoporosis,
this condition remains a serious public health issue. Adrenomedullin (AM) is a regulatory
peptide with reported activity on bone remodeling. To better understand this relationship
we built an inducible knockout for AM. An outstanding feature of knockout mice is
their heavier weight due, in part, to the presence of denser bones. The femur of
knockout animals was denser, had more trabeculae, and a thicker growth plate than
wild type littermates. The endocrine influence of AM on bone seems to be elicited
through an indirect mechanism involving, at least, the regulation of insulin, glucose,
ghrelin, and calcitonin gene-related peptide (CGRP). To confirm the data we performed
a pharmacological approach using the AM inhibitor 16311 in a mouse model of
osteoporosis. Ovariectomized females showed significant bone mass loss, whereas
ovariectomized females treated with 16311 had similar bone density to sham operated
females. In conclusion, we propose the use of AM inhibitors for the treatment of
osteoporosis and other conditions leading to the loss of bone mass.
Keywords: adrenomedullin, inducible knockout, bone physiology, ovariectomized mice, osteoporosis, small
molecule inhibitor
INTRODUCTION
Osteoporosis is a serious public health issue, especially taking into consideration the growing
aging population in developed countries. Osteoporosis is characterized by a reduction in bones
mineral density and a deterioration of bone microarchitecture, which results in a higher risk
of bone fractures (NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis,
and Therapy, 2001; Sambrook and Cooper, 2006). Osteoporosis is more frequent in women,
especially after menopause. Estrogen deficiency increases bone resorption, leading to a net
loss of bone mass by unbalanced bone deposition by osteoblasts and bone resorption by
osteoclasts (Andreopoulou and Bockman, 2015). Nowadays, two major classes of treatments
are applied to osteoporosis patients: (i) antiresorptive medications which prevent bone loss
by blocking osteoclast formation, survival or activity, such as bisphosphonates, the RANKL-
neutralizing monoclonal antibody, denosumab, and cathepsin K inhibitors, such as odanacatib;
and (ii) anabolic agents which stimulate osteoblasts, such as PTH1-34 (teriparatide), which is
currently approved as a daily injection, and other analogs of PTH and PTHrP which are in
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development (Makras et al., 2015). In any case, osteoporosis
patients could benefit from the generation of new drugs that
exploit novel biological pathways, yet unexplored.
Adrenomedullin (AM) is a 52 amino acid peptide with a
ubiquitous distribution andmany physiological functions (Lopez
and Martinez, 2002), one of which is the regulation of insulin
secretion (Martinez et al., 1996). AM is coded by the Adm gene
located in mouse chromosome 7. The AM receptor consists on
a 7-transmembrane domain protein called calcitonin receptor-
like receptor (CLR) in combination with a single transmembrane
domain protein known as receptor activity modifying protein
(RAMP) (McLatchie et al., 1998). Using immunohistochemical
techniques, it has been shown that AM is expressed in the
developing chick limb buds (Seghatoleslami et al., 2002) and
in chondrocytes and osteoblasts in the bone’s growth plate
(Montuenga et al., 1997), suggesting a potential role in bone
development. It has also been shown that AMbinds to osteoblasts
(Naot et al., 2001), inducing the growth of both osteoblasts
(Cornish et al., 1997) and chondrocytes (Cornish et al., 2003)
in vitro. In addition, AM reduces apoptotic cell death in serum-
starved osteoblasts (Uzan et al., 2008). All these actions result
in a net bone mass increase in ex vivo experiments (Cornish
et al., 1997; Siclari et al., 2014). To carry out formal studies on
the correlation between AM and bone development in vivo, a
knockout model for either AM or its receptors is needed. Results
from several groups have shown that early abrogation of the
gene coding for AM or some of its receptor components results
in 100% embryo lethality due to serious vascular abnormalities
(Caron and Smithies, 2001; Shindo et al., 2001; Dackor et al.,
2006). To circumvent this problem, we developed a conditional
knockout for AMusingCre/loxP technology and have shown that
it works well when targeting specific cell types such as neurons
(Fernandez et al., 2008), endothelial cells (Koyama et al., 2013),
or club cells in the lung (Garcia-Sanmartin et al., 2016). Here
we describe the methodology to generate an inducible model
in which the AM gene can be eliminated in adult mice. These
animals survive the abrogation of the gene and constitute a good
model to study the physiological implications of AM, including
its impact on bone biology.
Several pharmacological interventions have been described
to reduce the physiological activity of AM. These include
a monoclonal antibody (Martinez et al., 1996), polyclonal
antibodies against either the peptide (Martinez et al., 1995; Ouafik
et al., 2002) or the receptors (Kaafarani et al., 2009), the peptide
fragment AM22−52 (Ishikawa et al., 2003), and small interfering
RNAs (Ramachandran et al., 2007). In addition, several small
molecules have been identified which can either increase or
decrease AM functions (Martinez et al., 2004a; Roldos et al.,
2008). One of these, the inhibitory molecule 16311, has been used
in this study to demonstrate pharmacologically the effects of AM
inhibition in a mouse model of osteoporosis.
MATERIALS AND METHODS
Generation of Inducible Knockout Mice
Mice where the Adm gene was surrounded by loxP sequences
(“floxed”) were generated in our lab and previously characterized
(Fernandez et al., 2008). These animals were crossed with
transgenic mice expressing Cre recombinase under the control
of a tetracycline-responsive promoter element (tetO) (Strain
Number 6234, The Jackson Laboratory, Bar Arbor, ME) and
with mutant mice having widespread expression of an optimized
form of reverse tetracycline-controlled transactivator (rtTA-M2)
protein (Strain Number 6965, The Jackson Laboratory). All three
strains had been previously backcrossed to a C57BL/6 genetic
background for several generations. Triple transgenic animals are
viable and lead a normal life. For experiments, the following two
genotypes were selected: normal controls (homozygous for the
Adm wild type allele, tetO-Cre, and rtTA) and knockout animals
(homozygous for the “floxed” Adm allele, tetO-Cre, and rtTA).
All procedures involving animals were carried out in
accordance with the European Communities Council Directive
(2010/63/UE) and Spanish legislation (RD53/2013) on animal
experiments and with approval from the ethical committee
on animal welfare of our institution (Órgano Encargado del
Bienestar Animal del Centro de Investigación Biomédica de La
Rioja, OEBA-CIBIR). Every week, animals were weighed and
inspected to ensure a healthy status. Humane endpoints were
defined (piloerection, lack of movement, protective posture,
significant weight loss) and animals expressing those symptoms
were euthanized. A symptom-free survival curve was built
using those data. For euthanasia, animals were intraperitoneally
injected with a lethal dose of anesthetic: 300mg/Kg ketamine
(Imalgene, Merial Laboratorios, Barcelona, Spain) + 30 mg/Kg
xylazine (Xilagesic, Proyma Ganadera, Ciudad Real, Spain). After
organ collection, mice were decapitated to ensure death.
Deletion Induction and Molecular
Comprobation
Male and female 9 week-old mice of both genotypes (control
and “floxed” mice) were exposed to 2mg/ml doxycycline in the
drinking water, supplemented with 5% sucrose, for 15 days.
After this period, mice were provided with regular water and
allowed to rest for at least 4 weeks before performing any
experiments. At this point, a group of animals (n = 5 per
sex and genotype) were sacrificed and several organs collected
and frozen in liquid nitrogen. DNA was extracted and subjected
to PCR with primers located outside the loxP sequences: P1
(sense): AAGGGAAGTCCTGCTCCAGT, and P2 (antisense):
GCCTTAGCTCAGGTCCAGTG. The expected amplicon size is
2500 bp for the wild type allele and 600 bp after the Adm gene has
been eliminated.
RIA and ELISA Blood Protein
Determination
At the time of sacrifice, blood (n = 40) was collected from
the heart and serum was prepared and frozen until further
analysis. The concentrations of AM were determined using a
commercially available RIA kit (Phoenix Pharmaceuticals, Inc.,
Karlsruhe, Germany). Samples (1ml) were initially diluted in
an equal volume of 0.1% alkali-treated casein in PBS, pH
7.4, and applied to pre-washed reverse-phase Sep-Pak C-18
cartridges (Waters Corp., Milford, MA). The peptide fraction
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was eluted from the C18 matrix with 3ml 80% isopropanol
containing 0.125N HCl and freeze-dried overnight, as described
(Martinez et al., 1999). AM levels found in lyophilized
extracts were then determined by RIA following manufacturer’s
instructions. Commercially available ELISA kits for acetylated
ghrelin (Millipore Corporation, St. Charles, MO) and CGRP
(USCNLife Sciences, Beijing, China) were purchased and peptide
levels were quantified following manufacturer’s instructions.
RNA Isolation and Quantitative Real Time
PCR (qRT-PCR)
Tissues were homogenized with TRIzol (Invitrogen, Madrid,
Spain) and RNA was isolated with RNeasy Mini kit (Qiagen,
Germantown, MD). Three micrograms of total RNAwere treated
with 0.5µl DNAseI (Invitrogen) and reverse-transcribed into
first-strand cDNA using random primers and the SuperScript
III kit (Invitrogen). Reverse transcriptase was omitted in control
reactions, where the absence of PCR-amplified DNA confirmed
lack of contamination from genomic DNA. Resulting cDNA
was mixed with SYBR Green PCR Master Mix (Invitrogen)
for quantitative real time polymerase chain reaction (qRT-PCR)
using 0.3µM forward and reverse oligonucleotide primers (AMf:
ATT GAA CAG TCG GGC GAG TA; AMr: CTT GGT CTT
GGG TTC CTC TG; GAPDHf: CAT GTT CCA GTA TGA
CTC CAC TC; GAPDHr: GGC CTC ACC CCA TTT GAT
GT). Quantitative measures were performed using a 7300 Real
Time PCR System (Applied Biosystems, Carlsbad, CA). Cycling
conditions were an initial denaturation at 95◦C for 10min,
followed by 40 cycles of 95◦C for 15 s and 60◦C for 1min. At
the end, a dissociation curve was implemented from 60 to 95◦C
to validate amplicon specificity. Gene expression was calculated
using absolute quantification by interpolation into a standard
curve. All values were divided by the expression of the house
keeping gene GAPDH.
Blood Pressure Measurements
Blood pressure was measured in conscious animals (n = 32)
by the tail-cuff method (CODA, Kent Scientific, Torrington,
CT). Briefly, each animal was acclimated for at least 10
practice sessions for a minimum of 15min, then blood pressure
parameters were recorded during 5 consecutive days. In each
recording session, 1 set of 5 acclimation cycles followed by 3 sets
of 10 acquisition cycles were performed, and the average of the
last 20 successful recordings was used for calculating systolic and
diastolic blood pressure, heart rate, tail blood flow, and tail blood
volume.
Glucose Tolerance Tests
Mice (n = 40) were fasted for 6 h and blood samples were
collected from the tail vein. Glucose levels were measured
with a clinical monitor (Contour XT, Bayer, Madrid, Spain) to
establish a baseline glucose level (T0). They were then injected
intraperitoneally with 2.0 g glucose/kg body weight. Blood
samples were taken at 15, 30, 60, and 120min after injection and
glucose measured as before.
Bone Imaging, Histology, and
Immunohistochemistry
At the time of sacrifice (n = 40), several tissues including
femur, pancreas, stomach, liver, and abdominal fat, were weighed
and fixed in 10% buffered formalin. Microtomography of the
femurs was carried out in a blinded fashion to define the bone
volume, as well as the bone density among the different groups.
The image files (DICOM- Digital Imaging and Communication
in Medicine) provided by the microCT were the main input
for building the geometric model of the femurs. Images of the
mouse legs were obtained by a rotational scanning of 360◦. A
GE Healthcare eXplore locus SP microCT was used, with an
x-ray filter number 3, 75 kV voltage, and 90mA power. The
resolution of the equipment was 34µm. Six hundred DICOM
files were obtained for each sample (one image for each rotation
of 1.06◦). The quality of the final model and its similarity with
the original sample are directly related to the degree of resolution
and the number of segmented images. The volume segmentation
was made by sweeping all the scanned slides. A phantom with
known density was used to normalize values. Bone mass was
expressed either as Hounsfield units or as the bone volume to
total volume fraction (BV/TV) (Jeyabalan et al., 2013; Kang et al.,
2014). After the images had been taken, bone samples were
decalcified with Biodec R (Bio-Optica,Milano, Italy), dehydrated,
and embedded in paraffin. All other tissues were paraffin-
embedded without decalcification. Tissue sections (3-µm thick)
were stained with hematoxylin-eosin and Masson’s trichrome.
The proportion trabecular to laminar bone was calculated with
image processing software (ImageJ) and growth plate thickness
was measured in all specimens.
In addition, fragments of duodenum from both genotypes
were fixed in 10% buffered formalin, paraffin embedded, and
sections were immunohistochemically stained for Lyve1. Internal
peroxidase activity was blocked by incubation with H2O2 in
methanol and antigen retrieval was accomplished in 10mM
sodium citrate, 0.5% Tween 20, pH 6.0, for 20min at 95◦C. Non-
specific binding was blocked with normal goat serum. A rabbit
anti-Lyve1 antibody (Abcam, Cambridge, UK) was applied at
a concentration 1:1000 at 4◦C overnight. A biotinylated goat
anti-rabbit immunoglobulin (1:200), the Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA), and diaminobenzydine
(Sigma-Aldrich, Madrid, Spain) were used to detect the primary
antibody. At the end, sections were lightly counterstained with
hematoxylin.
Osteoporosis Mouse Model
Forty 8-week old female C57BL/6mice (Charles River, Barcelona,
Spain) were used for this experiment. Twenty of them were
ovariectomized and the other 20 were sham operated. On each
group, half of the mice (n = 10) were injected i.p. 3 times a
week with PBS as a vehicle, whereas the other 10 mice received
20 nmols/kg of small molecule 16311 dissolved in PBS. After 5
weeks of treatment, mice were deeply anesthesized, blood was
extracted from the heart to study toxicitymarkers, and the femurs
were fixed in 10% buffered formalin. Bone density was analyzed
by micro-CT as above. Small molecule 16311 was custom made
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by Centro de Química Aplicada y Biotecnología (University of
Alcalá, Madrid, Spain). Concentration and dosing regime was
chosen based on previous studies with blood pressure regulation
(Martinez et al., 2004a).
Statistics
Symptom-free survival data at 100 weeks of age were displayed
as Kaplan-Meier curves and analyzed with Log-rank Mantel-Cox
statistics. Blood pressure parameters were analyzed by Student’s
t-test after confirming data normalcy and homoscedasticity.
Glucose tolerance tests, weight patterns, and osteoporosis
treatments were studied with 2-way ANOVA. Kruskal-Wallis
followed by Dunn’s post-hoc test was used for all other
data. All studies were performed with GraphPad Prism
version 5.02.
RESULTS
Characterization of the Inducible Knockout
Mice with the proper genotype were obtained and subjected
to doxycycline treatment for 2 weeks. Confirmation of Adm
deletion was performed by PCR in numerous organs (brain,
pituitary, lung, heart, liver, pancreas, small intestine, colon,
gonads, kidney, skeletal muscle, and several others). In all
the WT animals a band of around 2500 bp was obtained,
indicating the presence of the gene despite the treatment with
doxycycline. In contrast, all tissues obtained from the KO
mice presented a single band of ∼600 bp, showing a complete
deletion of Adm (Figure 1A). To test whether this gene targeting
resulted in expression reduction, quantitative real time PCR
was performed in several organs, including the lung and liver,
6 weeks after initiating doxycycline treatment, and a marked
reduction in AMmRNAwas achieved (Figure 1B). Furthermore,
levels of AM were measured in blood serum. KO animals
had significantly lower levels of AM than their WT littermates
(Figure 1C). Calcitonin gene-related peptide (CGRP) belongs
to the same peptide family as AM and has been shown to
increase when AM levels are reduced (Fernandez et al., 2010).
We checked the levels of this peptide in the animals lacking AM
by ELISA and we found a significant increase when compared
with WT animals (Figure 1D). Symptom-free survival of the
gene-targeted mice was followed up to 100 weeks. KO mice
had a significantly lower survival than their WT littermates
(Figure 1E). Survival began to differ between genotypes at
94 weeks, providing a long time to perform physiological
experiments in Adm-null mice. This observation is in sharp
contrast with what happens in fetal mice where lack of this
gene results in embryo lethality (Caron and Smithies, 2001).
The more profusely studied physiological action of AM is blood
pressure regulation (Lopez and Martinez, 2002), so we tested
how the total elimination of Adm influenced this parameter.
There was a significant decrease in diastolic blood pressure in
the KOs whereas there was no change in systolic blood pressure.
In addition, KO animals had a higher pulse frequency and lower
blood flow rate and tail blood volume than theirWT counterparts
(Table 1).
Knockout Adm Mice Gain Weight Rapidly
We observed that the population of KO mice gained weight
rapidly after exposure to doxycycline and consequent induction
of gene deletion (Figure 2A), with a mean overweight of 4.5 g
per animal. We tried to identify the cause for these changes and
different organs were studied. The weight of several organs is
shown in Table 2. No significant differences were found between
genotypes. The only difference we found was the presence
of denser bones in the KOs (see below). Interestingly, some
individual mice (about 12% of the male KO animals) gained a lot
of weight in short periods of time, being able to lose it again after
a few days (Figures 2B,C). At the peak of their weight gain, these
animals suffered from transitory generalized interstitial edema,
a condition also known as anasarca. At this time, histological
observation showed that the connective tissue was swamped by
interstitial fluid and the lymphatic vessels were largely distended
(Figure 2D). To check whether this lymphedema was present in
KO animals not affected by anasarca, we studied the morphology
of lymphatic vessels in the intestine staining them with the
specific marker Lyve1, and no major differences were observed
(Figures 2E,F).
KO Mice Present Denser Bones
Histology of the femur showed that the relative surface occupied
by trabeculae was higher in KO animals than in their WT
counterparts (Figures 3A,B,F). In addition, the growth plate
at the epiphysis was thicker in the animals lacking AM
(Figures 3C,D,G). Furthermore, micro-CT measurements of the
femur also showed a higher bone density in the KOs (Figure 3E),
with no changes in bone length.
Knockout Mice Gain Bone Mass through
an Indirect Mechanism
Since previous in vitro reports indicated that AM increases bone
mass (Cornish et al., 1997, 2003; Naot et al., 2001; Uzan et al.,
2008), we would have expected a lower bone mass in animals
lackingAdm. But, since we obtained the reverse result (Figure 3),
we hypothesized that our observations must be due to an indirect
systemic effect of AM. A possible mechanism may involve the
increase in CGRP shown in Figure 1D, since CGRP can induce
bone growth through stimulation of bone mesenchymal stem
cells (Liang et al., 2015). Also, AM has been shown to reduce
insulin secretion in the pancreas, thus increasing glucose levels
(Martinez et al., 1996). We tested whether glycemia was affected
in the KOs and found that animals lacking AM had lower fasting
basal glucose levels than their WT littermates (Figure 4A). These
differences in glycemia were also maintained through a glucose
tolerance test (Figure 4B). It has been shown that low glucose
induces ghrelin secretion from the stomach (Goldstein et al.,
2011). Accordingly, ghrelin levels in the blood of our KOs
are significantly higher than in the WTs as tested by ELISA
(Figure 4C). Closing the circle, the literature tells us that ghrelin
promotes bone formation either through the induction of growth
hormone or through growth hormone-independent mechanisms
(Tong et al., 2012; Delhanty et al., 2014b; Wee and Baldock,
2014).
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FIGURE 1 | Characterization of the knockout phenotype. (A) Liver and brain fresh tissue was collected from 5 wild type (WT) and 5 knockout (KO) male mice and
subjected to PCR with primers which distinguish the unmodified Adm gene (∼2500 bp) from the recombined allele (∼600 bp). (B) mRNA expression for AM was
determined in the lung and liver. Values represent a relative AM/GAPDH ratio (n = 6 per group, all males). (C) A radioimmunoassay for AM was performed in blood
serum from WT and KO animals (n = 12 per group, all males). (D) CGRP serum contents were calculated by ELISA (n = 6 per group, all males). (E) Mouse
symptom-free survival (n = 32, 16 males, 16 females) was followed up to 100 weeks of age and is represented by Kaplan-Meier curves. Statistically significant
differences between genotypes are expressed by asterisks. *p < 0.05; **p < 0.01; ***p < 0.001.
TABLE 1 | Blood pressure parameters as measured with the CODA system
in wild type (WT) and knockout (KO) mice (n = 16 per group).
WT KO p
Systolic blood pressure (mm Hg) 138.7± 1.15 140.0± 0.99 0.37 n.s.
Diastolic blood pressure (mm Hg) 108.5± 1.00 103.3± 0.95 0.0002 ***
Pulse (beats/min) 705.1± 3.18 719.2± 3.74 0.0042 **
Blood flow rate (mL/min) 15.9± 0.34 11.8± 0.25 <0.0001 ***
Tail blood volume (µL) 29.6± 0.66 26.3± 0.48 <0.0001 ***
Values are mean ± SEM of all valid measurements. Statistical significance was calculated
with Student’s t test. **p < 0.01; ***p < 0.001.
An AM Inhibitor Prevents Osteoporosis
If our hypothesis expressed above is correct, any effective
inhibitor of AM should increase bone mass or prevent its loss
in an in vivo setting. To test this, we used an osteoporosis
mouse model where ovariectomy produces estrogen deficiency
and bone loss. Small molecule 16311 was used as an AM inhibitor
(Martinez et al., 2004a). As expected, untreated ovariectomized
females suffered significant bone loss when compared with fertile
females (Figure 5). Interestingly, treatment with 16311 had no
effect on normal females, but completely prevented bone loss
in ovariectomized mice (Figure 5). This was also confirmed by
histological observation of the bones (Figure 6). At the end of
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FIGURE 2 | Weight differences between genotypes. Mouse weight was
measured weekly from weaning (at 4 weeks of age) in males for both wild type
(WT) and knockout (KO) mice. (A) Following doxycycline treatment (weeks
9–11) and subsequent gene recombination, the mean weight of the KO mice
became significantly higher than that of their WT littermates. Each point
represents the mean ± SD of all mice (n = 10 per group). **p < 0.01; ***p
< 0.001. (B) Sporadically, individual KO mice (left) gained weight very rapidly,
becoming much larger than the WT controls (right). (C) Interestingly, following
the weight of individual mice through time, these large animals were able to
lose this accumulated weight very rapidly, as well, returning to the mean
weight of their genotype within a week. (D) Histological analysis of the tissues
of an animal at the peak of its weight gain shows a widespread interstitial
edema and lymphatic vessel occlusion (arrows). The image shows a section of
the neck area, close to a salivary gland, stained with hematoxylin-eosin. Bar =
100µm. Cross-sections of duodenum in WT (E) and KO (F) mice stained with
an antibody against Lyve1 (brown color) and counterstained with hematoxylin.
Bar = 50µm.
the treatment, blood was extracted and toxicity markers were
studied. Treatment with small molecule 16311 did not induce any
blood, liver, or renal toxicity at the concentrations and periodicity
used in this experiment (Table 3).
DISCUSSION
In this study we have shown that elimination of the gene
coding for AM in adult mice is compatible with life. AM
deficiency results in an increased weight of the animals which
is accompanied by an increase in bone density, at least in the
TABLE 2 | Relative weight, expressed as percentage of total body weight,
of several organs in wild type (WT), and knockout (KO) male mice.
WT KO p
Abdominal fat 0.68±0.08 0.79± 0.05 0.13
Pancreas 0.94±0.22 0.81± 0.19 0.16
Stomach 0.56±0.16 0.62± 0.06 0.25
Liver 4.62±0.46 5.05± 0.52 0.06
None of the differences reached statistical significance.
FIGURE 3 | Bone parameters in WT and KO mice. Histological sections of
the head of the femur in WT (A,C) and KO (B,D) animals, stained with
hematoxylin and eosin (A,B) or with Masson’s trichrome (C,D). Femur bone
density was measured in both genotypes (E). The ratio trabecular vs. laminar
bone (F) and the thickness of the growth plate (G) was calculated for both
genotypes. Each bar represents the mean ± SD of all mice. *p < 0.05; ***p
< 0.001. Bar for (A,B) = 500µm. Bar for (C,D) = 100µm.
femur. This increased bone mass may be achieved through an
indirect mechanism involving regulation of glycemia and ghrelin
and CGRP secretion. The hypothesis that AM inhibition could
prevent bone mass loss was demonstrated with a small molecule
inhibitor of AM in a mouse model of osteoporosis.
The choice of proper controls is an important step in any
experiment, but especially so when working with knockout
models. We had several theoretical options. One of them was
to compare mice with the same genotype (homozygous for the
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FIGURE 4 | Potential indirect mechanism of AM-dependent bone density regulation. (A) Basal fasting glucose levels were significantly lower in KO animals
than in their WT counterparts (n = 30 per group). (B) Following a glucose tolerance test, significant differences were observed in the blood glucose levels comparing
both genotypes, with the KO mice having lower values than the WT controls (n = 10 per group). (C) Acetylated ghrelin levels were measured in the blood of both
genotypes. In this case, the levels of active ghrelin were significantly higher in the KO animals (n = 10 per group). Each point represents the mean ± SD of all mice.
*p< 0.05; **p< 0.01; ***p< 0.001.
“floxed” allele, tetO-Cre, and rtTA) that were treated (KO) or
untreated (WT) with doxycycline. Recent studies have shown
that doxycycline is not just an antibiotic that kills bacteria and has
no influence in eukaryotic cells; on the contrary this tetracycline
modifies many cellular pathways in vertebrates (Larrayoz et al.,
2013), and therefore sharp differences between treated and
untreated animals may occur, independently of their genotype.
In addition, there is always the possibility of some leakage in the
control of the promoter, resulting in “WT” animals with partial
deletion of the gene (Backman et al., 2009). In consequence, we
decided to treat both the KO and the WT animals with the same
dose of doxycycline, choosing different genotypes that respond
(KO) or not (WT) to this treatment.
When looking at the circulating levels of AM in KO mice we
found a significant decrease of AM but these levels were higher
than expected, despite the AM mRNA expression being close to
zero. These results may be explained in two ways. First, we may
hypothesize the existence of a reservoir that keeps providing AM
even after the gene is eliminated. In fact, the existence of an AM
serum binding protein, complement factor H, was described (Pio
et al., 2001) and this protein is able to protect AM from MMP2-
mediated degradation (Martinez et al., 2004b). If this is the case,
a time-course analysis would determine how long it takes to
eliminate AM completely from the circulation of these mice. On
the other hand, there may be a cross-reactivity of the kit’s AM
antibody with other members of the peptide family, such as AM2
or intermedin, which shares a 28% overall sequence identity with
AM (Roh et al., 2004).
We observed that the diastolic blood pressure in the KOs
was lower than in the WT animals. This seems to run against
the generalized idea which identifies AM as a vasodilator
(Lopez and Martinez, 2002). Nevertheless, this issue is more
complex than initially perceived. Although AM is a vasodilator
when injected peripherally (Santiago et al., 1995), it acts as a
vasoconstrictor when injected into the brain, probably acting
through vascular nerve terminals (Takahashi et al., 1994).
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FIGURE 5 | Small molecule 16311 prevents bone loss. Female mice were
ovariectomized (OVX) or Sham operated (Sham) and then treated for 5 weeks
with PBS (as a vehicle) or with 20 nmols/kg of small molecule 16311 dissolved
in PBS, and the bone density of their femurs was measured by microCT
(expressed as BV/TV) (n = 10 female mice/group). As expected, untreated
ovariectomized mice suffered a significant bone loss when compared to Sham
females (**p < 0.01). On the other hand, ovariectomized females treated with
16311 had undistinguishable density from Sham controls (p > 0.05) and
significantly more bone density than untreated ovariectomized females
(#p < 0.05). Each bar represents the mean ± SD of all mice (n = 10 per
group).
Therefore, in a full-body knockout, the final outcome would
depend on which physiological fraction, peripheral, or central,
plays a more relevant role on blood pressure regulation. Similar
results to the ones obtained in our model have been described
when RAMP2, one of the components of the AM receptor, is
deleted from endothelial cells (Koyama et al., 2013). So, it appears
that the AM-regulated central control on vasodilatation is more
powerful than the peripheral one.
The rapid weight gains and losses observed in our KO mice
were unexpected. Careful observation of the animals, at the
time they reached the peak of their weight gain, confirmed
that this was due to generalized edema, which in some cases
could be classified as anasarca. This is in line with the hydrops
fetalis, a fetal generalized edema, which is described in all
embryo knockout models of this gene and its receptors (Caron
and Smithies, 2001; Shindo et al., 2001; Dackor et al., 2006).
Interestingly, all fetuses die in utero due to the dysregulation
of the blood and lymphatic vessels caused by the lack of AM
(Fritz-Six et al., 2008) but our animals were able to recover
swiftly and even lose all the extra weight in a few days. Obviously
we have to conclude that adult mice have in place some extra
mechanisms to deal with edema and are more protected than
fetuses. Fortunately, no edema formation was observed in the
ovarectomized females treated with small molecule 16311 or in
KO mice not suffering anasarca, suggesting that lymphatic vessel
blockade occurs only during these episodes.
Previous publications had centered their efforts on the effects
of AM on specific bone cell types in vitro (Cornish et al., 1997,
2003; Naot et al., 2001; Uzan et al., 2008) or in ex vivo organ
cultures (Cornish et al., 1997; Siclari et al., 2014), thus looking at
the local influences of AM. As it happens with many hormones,
FIGURE 6 | Small molecule 16311 prevents loss of trabeculae.
Representative histological sections of the head of the femur of animals in the
ovarectomy experiment stained with Masson’s trichrome. Photographs
represent sham-operated animals treated with PBS (A) or with the small
molecule (B) and ovarectomized females treated with PBS (C) or with the
small molecule (D). Bar = 500µm.
AM has autocrine, paracrine, and endocrine functions that may
be rather different (Larrayoz et al., 2014). This seems to be a clear
example where local autocrine/paracrine loops result in bone
deposition whereas long-distance endocrine signaling has the
reverse effect. As shown by our results, this differential endocrine
behavior may be elicited through indirect mechanisms involving
the regulation of CGRP, insulin, glycemia, and ghrelin levels,
although additional mechanisms may exist. CGRP belongs to the
same peptide family as AM and it also signals through CRL,
although using a different RAMP isoform (McLatchie et al.,
1998). Previous studies using a conditional AM knockout model
showed an increase in CGRP expression in the dorsal root
ganglia and spinal cord of animals lacking AM in the neurons
(Fernandez et al., 2010). Here we have shown that this peptide
is also upregulated in the inducible KO model. Since CGRP
has been involved in the recruitment and maturation of bone
mesenchymal stem cells (Liang et al., 2015), this may provide an
indirect mechanism linking AM reduction and increase of bone
mass.
As another possibility, AM has been shown to reduce insulin
secretion whereas a blocking monoclonal antibody against AM
was able to increase insulin release five-fold (Martinez et al.,
1996). This in turn would modulate blood glucose levels, being
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TABLE 3 | Toxicity analysis in the blood of ovariectomized (OVX) mice
treated and untreated with 16311.
OVX + PBS OVX + 16311
Biochemistry Urea (mg/dL) 18.21± 3.33 18.50±3.78
Creatinine (mg/dL) 0.13± 0.01 0.13±0.02
ALT (IU/L) 39.52± 2.33 42.80±7.08
AST (IU/L) 92.00± 5.62 82.20±7.75
ALKP (IU/L) 40.03± 34.27 43.60±35.63
GGT (IU/L) 1.14± 0.58 0.56±0.36
Hemogram MCV (%) 31.40± 0.33 30.58±0.31
RBC (106/µL) 7.66± 0.08 7.46±0.09
Hb (g/dL) 12.18± 0.15 11.78±0.17
WBC (103/µL) 6.10± 0.64 4.96±0.68
Values are the mean ± SEM of all animals in the group (n = 10 per group). All numbers
are within normal values for C57BL/6 mice.
lower in the KOs. Low glycemic levels induce ghrelin secretion
in the stomach through sympathetic neurons and the release
of norepinephrine (Goldstein et al., 2011). Then ghrelin favors
bone formation either in a direct way acting on osteoblasts (Ma
et al., 2015) or through the induction of growth hormone or IGF-
1 (Fukushima et al., 2005; Deng et al., 2008; Tong et al., 2012;
Delhanty et al., 2014a,b; Wee and Baldock, 2014).
Other publications seem to support our findings when
properly interpreted. For instance a study used the
peptide fragment AM22−52, trying to take advantage of its
immunomodulatory action, and found that it prevented bone
loss in a model of collagen-induced arthritis (Ah Kioon et al.,
2012). As explained above, this fragment is an AM inhibitor and,
as such, it has similar effects to our small molecule inhibitor.
Another recent publication was looking at the effects of AM
and its inhibitors on the growth of bone-affecting tumors. The
authors found that the inhibitory small molecule 16311, the same
we use in this paper, reduced tumor induced osteolysis in their
model (Siclari et al., 2014).
The potential clinical correlation between AM levels and
osteoporosis has not been extensively studied. A manuscript,
written in Chinese, found a significant increase of AM levels
in human subjects with primary osteoporosis (Lin et al., 2001).
Although it is difficult to establish whether this increase in
AM is the cause or an effect of osteoporosis, according to our
hypothesis, elevated levels of AM may result in a further loss of
bone density and AM inhibitors could be indicated. Recently,
it was found that a particular single nucleotide polymorphism
(SNP) close to the Adm gene was responsible for a significant
reduction in the circulating levels of AM (Cheung et al., 2011).
As a consequence, the carriers of the minor allele are strongly
protected against cancer (Martinez-Herrero andMartinez, 2013).
It would be interesting to test whether these individuals are also
protected from developing osteoporosis.
We found that small molecule 16311 was able to prevent
bone loss in a mouse model of osteoporosis without eliciting any
measurable toxicity, making this molecule a good candidate for a
first-in-class drug against osteoporosis. Since AM is a vasodilator,
most efficient inhibitors of this molecule should increase blood
pressure, and this has been shown for 16311 (Martinez et al.,
2004a). For the potential clinical development of this compound,
this feature may not be too desirable. Interestingly, among the
small molecules that were initially identified by their ability
to bind AM and to reduce AM-induced cAMP elevation,
there were some that did not increase blood pressure when
injected in rats (Martinez et al., 2004a). These included small
molecules 28086 and 37133. If these molecules are shown to
possess an osteoporosis prevention effect they may be even more
interesting than 16311 for further development. In the same
line of thought, any inhibitor of AM could offer benefits to
patients with diseases characterized by losses in bone mass. These
could include monoclonal and polyclonal antibodies (Martinez
et al., 1996; Ouafik et al., 2002; Kaafarani et al., 2009), inhibitory
peptide fragments such as AM22−52 (Ishikawa et al., 2003), or
small interfering RNA constructs (Ramachandran et al., 2007),
among others. Nevertheless, small molecules continue to capture
pharmacological attention due to their longer half-life and higher
stability than peptides and antibodies.
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